CD8 Depleted Donor Lymphocyte
PreclinicalBiologic
CD8 Depleted Donor Lymphocyte is one of 9 biologic programs targeting Allogeneic Stem Cell Transplantation. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Allogeneic Stem Cell Transplantation
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Cellcept
RochePhase 3
Tepadina
Jazz PharmaceuticalsPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Jakafi
IncytePhase 2
Prograf
VVeloxis Pharmaceuticals
Phase 2
Desferal
Jazz PharmaceuticalsPreclinical
Drugs Nivolumab
MM.D. Anderson Cancer Center
Phase 2
CD8 Depleted Donor Lymphocyte
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- MM.D. Anderson Cancer Center